The association alfa-enolase/plasmin is a new selective target for treating muscular pathologies

The association alfa-enolase/plasmin is a new selective target for treating muscular pathologies: Researchers at the Bellvitge Biomedical Research Institute (IDIBELL) have described a new selective target in muscle regeneration. This is the association of alpha-enolase protein and plasmin. The finding could be used to develop new treatments to regenerate muscular injuries or dystrophies. The study has been published in PLOS ONE journal

Dantrolene may help combat Duchenne muscular dystrophy in boys

Dantrolene may help combat Duchenne muscular dystrophy in boys: Drugs are currently being tested that show promise in treating patients with Duchenne muscular dystrophy (DMD), an inherited disease that affects about one in 3,600 boys and results in muscle degeneration and, eventually, death.
Now, scientists at UCLA have found a drug, already approved by the U.S. Food &Drug Administration and being used in humans, that provides a powerful boost to the therapy currently being tested in clinical trials. They hope this one-two punch used in combination will overcome the genetic mutations that cause DMD, restore a missing protein needed for proper muscle function and allow those affected by the disease to lead relatively normal lives.